Amylyx Pharmaceuticals, Inc. AMLX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s EPS (diluted)?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported EPS (diluted) of -$0.37 in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s EPS (diluted) changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s EPS (diluted) increased by 11.9% year-over-year, from -$0.42 to -$0.37.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s EPS (diluted) has grown at a -41.8% compound annual growth rate (CAGR), from -$13.31 to -$1.53.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.